Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
GHRP-2, also known as Growth Hormone-Releasing Peptide-2 or pralmorelin, is a synthetic hexapeptide studied as a growth hormone secretagogue and ghrelin receptor agonist. In research settings, GHRP-2 is used to study GHSR-1a signaling, pituitary growth hormone release, hypothalamic-pituitary regulation, appetite-related pathways, ACTH and cortisol response models, and the broader GH and IGF-1 axis. This 2026 guide explains what GHRP-2 is, how it differs from GHRH analogues such as sermorelin and CJC-1295 No DAC, how it compares with ipamorelin and GHRP-6, and what quality, documentation, storage and research-use-only standards matter when evaluating this peptide.
GHRP-2 is a synthetic growth hormone secretagogue peptide studied for activation of the ghrelin receptor, also called GHSR-1a. Unlike GHRH analogues such as sermorelin or CJC-1295 No DAC, GHRP-2 does not primarily act through the GHRH receptor. It is studied for ghrelin-receptor-mediated growth hormone release, hypothalamic-pituitary signaling, appetite-related pathways and secondary endocrine readouts such as ACTH, cortisol and prolactin in certain experimental models.
GHRP-2 belongs to the growth hormone secretagogue peptide category. It is a synthetic hexapeptide that has been studied for its ability to activate the ghrelin receptor pathway, influence pituitary growth hormone release and interact with hypothalamic-pituitary endocrine signaling.
GHRP-2 is not growth hormone and it is not a GHRH analogue. It is a research peptide that mimics part of the ghrelin signaling pathway, which can trigger GH-axis activity through the growth hormone secretagogue receptor.
For Luxara Labs, GHRP-2 should be framed as a research-use-only ghrelin receptor agonist and GH secretagogue research peptide. The most accurate discussion focuses on receptor biology, pituitary response, endocrine readouts, pathway comparisons and evidence limitations, not on consumer benefits, dosing, bodybuilding, anti-aging or human-use claims.
GHRP-2 is a synthetic growth hormone-releasing peptide and ghrelin receptor agonist studied in GH secretagogue research. It is structurally different from endogenous ghrelin, but it interacts with the growth hormone secretagogue receptor pathway that ghrelin also activates.
| Feature | GHRP-2 Detail | Research Interpretation |
|---|---|---|
| Common name | GHRP-2 | Primary research and supplier name for Growth Hormone-Releasing Peptide-2. |
| Other names | Pralmorelin, KP-102, GPA-748, growth hormone-releasing peptide 2 | Useful for identifying the compound across pharmacology and diagnostic literature. |
| Compound class | Synthetic hexapeptide | Belongs to the growth hormone secretagogue peptide category. |
| Common CAS number | 158861-67-7 | Common registry number associated with pralmorelin, GHRP-2. |
| Common sequence | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 | Sequence identity helps distinguish GHRP-2 from GHRP-6, hexarelin and ipamorelin. |
| Primary receptor | GHSR-1a | The ghrelin or growth hormone secretagogue receptor pathway. |
| Research-use status | Laboratory research only | Not for human consumption, veterinary use, diagnostic use, therapeutic use, hormone therapy, performance use or cosmetic use. |
The central research mechanism of GHRP-2 involves activation of GHSR-1a, the growth hormone secretagogue receptor. This receptor is also known as the ghrelin receptor and is expressed in tissues relevant to hypothalamic-pituitary signaling, appetite regulation and endocrine response models.
| Pathway Component | Research Role | Why It Matters for GHRP-2 |
|---|---|---|
| GHSR-1a | Growth hormone secretagogue receptor, also called the ghrelin receptor. | Primary receptor pathway used to interpret GHRP-2 activity. |
| Ghrelin pathway | Endogenous signaling system connected to GH release, appetite and energy balance. | GHRP-2 is studied as a synthetic ghrelin receptor agonist, not as endogenous ghrelin itself. |
| Pituitary somatotroph cells | Cells responsible for GH synthesis and release. | GH release is a major readout in GHRP-2 research models. |
| Hypothalamic signaling | Regulatory control layer involving GHRH, somatostatin and ghrelin-related inputs. | Helps explain why GHRP-2 effects may differ from direct GHRH receptor stimulation. |
| GH and IGF-1 axis | Downstream endocrine pathway connected to pituitary GH release and peripheral IGF-1 signaling. | Useful for GH-axis research, but not a basis for human-use or outcome claims. |
| ACTH, cortisol and prolactin response | Secondary endocrine readouts reported in some GHRP-2 and hexarelin studies. | Important because GHRP-2 may not be fully specific to GH-only response models. |
GHRP-2 research is most relevant to ghrelin receptor signaling, GH secretagogue biology, pituitary responsiveness, GH reserve evaluation models, appetite-related pathways, and comparative GH-axis peptide research.
| Research Area | What Is Being Studied | Important Limitation |
|---|---|---|
| Ghrelin receptor signaling | Activation of GHSR-1a and downstream endocrine signaling. | Receptor activation should not be converted into consumer-use claims. |
| GH secretagogue research | How synthetic secretagogues stimulate pituitary GH release. | GH response is a research readout, not proof of body-composition, recovery or anti-aging outcomes. |
| GH reserve and diagnostic context | GHRP-2 has been studied as a provocative agent for assessing GH secretory capacity. | Diagnostic literature should not be converted into instructions for research materials. |
| Hypothalamic-pituitary regulation | Interaction between ghrelin receptor signaling, GHRH, somatostatin and pituitary output. | Endocrine response depends heavily on model context and feedback controls. |
| Appetite and energy-balance research | Ghrelin receptor biology, food-intake signaling and metabolic regulation models. | Appetite-related findings should not be presented as use guidance. |
| Comparative secretagogue research | Comparison with ipamorelin, GHRP-6, hexarelin and GHRH analogues. | Different compounds vary in selectivity, endocrine readouts and receptor profile. |
GHRP-2 is often grouped with GH-axis peptides, but its receptor pathway is distinct. The most important comparison is GHSR-1a pathway compounds versus GHRH receptor pathway compounds.
| Compound | Primary Research Pathway | How It Differs From GHRP-2 |
|---|---|---|
| GHRP-2 | GHSR-1a, ghrelin receptor, GH secretagogue pathway | Synthetic hexapeptide studied for ghrelin receptor activation and GH secretagogue response. |
| Ipamorelin | GHSR-1a, ghrelin receptor pathway | Same broad receptor category, but often discussed as a more selective GH secretagogue model. |
| GHRP-6 | GHSR-1a, ghrelin receptor pathway | Similar GHRP category, but historically associated with stronger appetite-related research interest. |
| Hexarelin | GHSR-1a and GH secretagogue research | Related synthetic secretagogue with its own endocrine and cardiovascular research profile. |
| CJC-1295 No DAC | GHRH receptor signaling | GHRH analogue, not a ghrelin receptor agonist. |
| Sermorelin | GHRH(1-29)NH2 and GHRH receptor signaling | Active GHRH fragment, not a GHSR-1a agonist. |
| Tesamorelin | GHRH analogue and GH/IGF-1 axis | GHRH receptor pathway compound with specific visceral-adiposity research context. |
GHRP-2, GHRP-6, ipamorelin and hexarelin are ghrelin receptor secretagogue research peptides. Sermorelin, CJC-1295 No DAC and tesamorelin are GHRH receptor research peptides. They all connect to GH-axis research, but they do not all act through the same receptor system.
GHRP-2 has a substantial research history across GH secretagogue pharmacology, ghrelin receptor biology, diagnostic GH testing, endocrine response studies and animal models. Interpretation should remain pathway-specific and research-only.
| Evidence Area | What the Literature Reports | Research Interpretation |
|---|---|---|
| Ghrelin receptor agonism | Published research describes GHRP-2 as a synthetic agonist of ghrelin and the growth hormone secretagogue receptor. | Supports its classification as a GHSR-1a pathway compound. |
| GH secretagogue response | Human and animal studies report GH release after GHRP-2 exposure in controlled experimental settings. | GH response is a pathway readout, not a direct claim of clinical or consumer outcomes. |
| ACTH, cortisol and prolactin effects | Comparative studies found that GHRP-2 and hexarelin can affect GH as well as ACTH, cortisol and prolactin readouts. | Important because GHRP-2 may not be interpreted as a GH-only research signal. |
| Diagnostic GH reserve testing | GHRP-2 has been studied for evaluating GH secretory capacity and growth hormone deficiency diagnostic models. | Diagnostic literature should not be converted into research-material instructions or human-use guidance. |
| Appetite and food intake models | GHRP-2 research has reported ghrelin-like appetite and food intake effects in certain models. | Appetite-related findings should remain mechanistic and not become use recommendations. |
| Anti-inflammatory animal models | GHRP-2 has been studied in arthritic rat models as a ghrelin agonist with inflammatory-pathway relevance. | Animal inflammatory research should not be converted into arthritis, joint or therapeutic claims. |
GHRP-2 is biologically interesting because it connects ghrelin receptor signaling to pituitary GH release and broader endocrine response models. That same breadth requires careful interpretation because GH secretagogue activity may interact with appetite signaling, ACTH, cortisol, prolactin, GHRH and somatostatin feedback systems.
The strongest scientific framing is conservative: GHRP-2 is a synthetic hexapeptide used to study GHSR-1a activation, ghrelin-like signaling, GH secretagogue response and endocrine pathway interactions in controlled laboratory models.
Because GHRP-2 is closely related to other GH secretagogue peptides, quality evaluation should focus on sequence identity, purity, lot-level traceability, analytical documentation, storage guidance and clear research-use-only labeling.
| Standard | Why It Matters |
|---|---|
| Batch-specific COA | Connects the material to lot-level analytical documentation. |
| HPLC purity verification | Supports purity evaluation and impurity visibility. |
| Mass spectrometry identity confirmation | Supports molecular identity confirmation and helps distinguish related GH secretagogues. |
| Sequence clarity | Reduces confusion between GHRP-2, GHRP-6, hexarelin and ipamorelin. |
| Clear compound naming | Should clearly identify GHRP-2, pralmorelin or KP-102 where relevant. |
| Storage and handling guidance | Reduces avoidable degradation, moisture exposure and freeze-thaw variability. |
| Research-use-only labeling | Keeps the material separated from consumer, clinical, hormone therapy, performance, anti-aging or human-use positioning. |
These answers cover the most common GHRP-2, pralmorelin, ghrelin receptor, GHSR-1a and GH secretagogue research questions in 2026.
GHRP-2 is a synthetic growth hormone-releasing peptide and ghrelin receptor agonist studied in GH secretagogue research. It is also known as pralmorelin, KP-102 and growth hormone-releasing peptide 2.
GHRP-2 is studied primarily as an agonist of GHSR-1a, the growth hormone secretagogue receptor. This receptor is also commonly called the ghrelin receptor.
No. GHRP-2 is not growth hormone. It is a GH secretagogue research peptide studied for ghrelin receptor activation and pituitary GH release models.
No. GHRP-2 is not a GHRH analogue. It acts through the ghrelin receptor pathway, while sermorelin, CJC-1295 No DAC and tesamorelin act through the GHRH receptor pathway.
The common CAS number associated with pralmorelin, GHRP-2, is 158861-67-7. Researchers should verify exact salt form, molecular identity, purity and supplier documentation when comparing materials.
GHRP-2 and ipamorelin are both studied through the ghrelin receptor pathway, but they differ in structure, selectivity and endocrine response profile. Ipamorelin is often discussed as a more selective GH secretagogue research model.
GHRP-2 and GHRP-6 are both synthetic GH secretagogue peptides, but they differ in sequence and research profile. GHRP-6 is often discussed more heavily in appetite-related ghrelin pathway research.
No. Luxara Labs GHRP-2 is supplied strictly for laboratory research use only. It is not intended for human consumption, veterinary use, diagnostic use, therapeutic use, hormone therapy, performance use or cosmetic use.
Researchers should look for batch-specific COAs, HPLC purity documentation, mass spectrometry identity confirmation, sequence clarity, lot numbers, storage guidance and research-use-only labeling.
Yes, but they should not be treated as the same mechanism. GHRP-2 is a ghrelin receptor secretagogue peptide, while CJC-1295 No DAC is a GHRH receptor analogue. Both connect to GH-axis research through different receptor pathways.
These references support the GHRP-2, pralmorelin, ghrelin receptor, GHSR-1a, GH secretagogue, pituitary response, endocrine readout and research-use context discussed on this page.
Join our list and get an instant 10% discount code — valid for first-time buyers.
